Formycon

Azione

ISIN: DE000A1EWVY8

Ticker: FYB

DE000A1EWVY8

FYB

Price

Discussione su FYB

Messaggi

Hannah B.

@HannahBaker

6G·

Hi everyone, I have previously written about CDMOs, which play an important role in the pharmaceutical industry. These organizations provide comprehensive services ranging from drug development to manufacturing. They allow pharmaceutical companies to outsource their manufacturing capabilities and focus on their core competencies. In this context, I would like to give some examples of CDMOs and also talk about biosimilars, in particular Formycon $FYB (+0,16%) a German company that is active in this area. I learned about Formycon through @cashwithhead who shared interesting insights about them.

Some examples of CDMO companies are:

Lonza Group: a leading Swiss company specializing in biologics and small molecules.
Catalent: Based in the USA, Catalent focuses on drug delivery technologies.
Thermo Fisher Scientific: This company provides comprehensive CDMO services and generates significant revenues in its business areas.

Biosimilars are biological medical products that are highly similar to already approved reference products and differ only in minor clinically inactive components. They are developed to offer similar efficacy and safety profiles, possibly at a lower cost.

An example of a biosimilar company is Formycon AG, a German company. Formycon is a major developer of biosimilars and focuses on the entire life cycle from development to regulatory approval. The company is known for its innovative approaches to creating biosimilar therapies.

Another example would be Biogen, which is active in the field of biosimilars. Biogen recently launched TOFIDENCE (tocilizumab-bavi), a biosimilar that references Actemra. TOFIDENCE was the first FDA-approved tocilizumab biosimilar in the U.S. and offers patients a more cost-effective treatment option for conditions such as rheumatoid arthritis.

Other global market leaders in biosimilars include:

Novartis AG
Pfizer Inc.
Amgen Inc.
Dr. Reddy's Laboratories

Did you already know that? I have to be honest and say that I didn't know. I hope I can offer you some added value with this article and broaden your horizons a little. Do you have any of the stocks mentioned in your portfolio?

Yours, Hani 🤗

Hannah B.

@HannahBaker

1Settimana·

A remarkable trend is emerging in the pharmaceutical industry: instead of relying on vertical integration, more and more companies are turning to Contract Development and Manufacturing Organizations (CDMOs). This development is fundamentally changing the industry and offers both opportunities and challenges.

CDMOs are specialized service providers that support pharmaceutical companies in the development and manufacture of drugs. In contrast to vertical integration, where companies take over all production steps themselves, collaboration with CDMOs enables a more flexible and often more cost-effective approach.

One of the main reasons for this change is the increasing complexity of drug development. Modern therapies, such as cell and gene therapies, require highly specialized expertise and advanced technologies. CDMOs can specialize in certain areas and thus build up expertise that would be difficult for individual pharmaceutical companies to achieve.

In addition, CDMOs offer flexibility in terms of production capacity. Pharmaceutical companies can scale up as needed without having to invest in their own production facilities. This is particularly advantageous in a market characterized by rapid changes and uncertain demand forecasts.

The COVID-19 pandemic has reinforced this trend. The rapid development and production of vaccines would hardly have been possible without the support of CDMOs. Many of the new mRNA vaccines have been produced by CDMOs, underlining their importance to the industry.

Another advantage of working with CDMOs is the opportunity for pharmaceutical companies to focus on their core competencies. While CDMOs take on the complex tasks of development and manufacturing, pharmaceutical companies can focus on research, clinical trials and commercialization2.

Despite these benefits, the shift to CDMO use also brings challenges. Quality control, contract management and maintaining trade secrets require careful planning and monitoring. Nevertheless, for many companies, the benefits outweigh the challenges.

The future of the pharmaceutical industry appears to be closely linked to the development of CDMOs. As the industry evolves, CDMOs are likely to play an even greater role, particularly in the development and manufacture of complex biopharmaceuticals and personalized medicine.

Overall, this trend shows that the pharmaceutical industry is increasingly relying on specialization and collaboration to drive innovation and operate more efficiently. The partnership between pharmaceutical companies and CDMOs could be the key to overcoming the challenges of modern drug development and ultimately developing better therapies for patients. [FT]

ThemenmitKopf

@topicswithhead

2Settimana·

Another depot update. Values are not quite correct but the reference value is. The crypto values are completely wrong but I have no idea where the entry price is (made kind of annoying at Coinbase). The best positions at the moment are $SOFI (+1,52%)
$FTNT (-0,37%)
$D05 (-0,46%) . The interesting values for me are $BNTX (-0,05%)
$FYB (+0,16%)
$SNOW (-0,02%)

+ 2

21 Commenti

ThemenmitKopf@topicswithhead

2Settimana

Update many values are wrong Biontech, for example, is 28%. Nevertheless hopefully interesting

•

Friedrich

@Moneybagger

1Anno·

$FYB (+0,16%) Formycon has much more to offer, both Novartis/Sandoz and Fresenius are interested in the company according to stock market information. However, a takeover now would be much too early and bad for shareholders. Now already a biosimilar in the market, more will follow from 2024/2025 it will be really interesting. The 16% increase in the share price today was just the beginning. Price targets 500 - 1000 €. Thus a 10 bagger. Read the 60 page report "Formycon the next Tenbagger", available at Amazon.

How$y 🗽

@Howsy

3Anno·

Opinione per $FYB

Besides BioNTech, the Formycon AG share is my second Corona bet. Unfortunately, it has not yet worked out in this case. With an entry at approx. 65€, I am now at approx. -20% return 🆘.

What does Formycon do?

"Formycon continues to advance the development of its COVID-19 drug candidate FYB207. An expansion of preclinical efficacy testing is planned, the company reported Wednesday. Most recently, FY207 had produced multiple positive results, but at the same time is still far from being used in everyday life."

That sounds bullish for now. The results of the first clinical studies and a possible subsequent approval will determine to what extent a price rocket will ignite here.

https://www.4investors.de/nachrichten/boerse.php?sektion=stock&ID=155248

Titoli di tendenza

I migliori creatori della settimana